Comparison of Pharmacokinetics of and Effect on Systemic VEGF Levels in Age Related Macular Degeneration Patients
Status:
Unknown status
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
To demonstrate the effects of Lucentis (ranibizumab), Avastin ( bevacizumab), and Eylea (
aflibercept) on the levels of naturally occurring Vascular Endothelial Growth Factor (VEGF)
in the systemic circulation of Age Related Macular Degeneration patients currently treated
with these medications.